Biocon sees mid-teens revenue growth on biosimilars, generics push

The biosimilars business accounted for 58% of Biocon's overall revenue in FY25. Biocon Biologics had said it would likely list itself on the exchanges by March 2026. However, after its January-March earnings, it said its board is setting up a committee to evaluate strategic restructuring options.

Industry